Oncternal Therapeutics Inc. buy Brookline Capital Management
Start price
11.03.23
/
50%
€0.70
Target price
11.03.24
-
Performance (%)
-62.03%
End price
12.03.24
-
Summary
This prediction is currently being closed. The BUY prediction by Brookline_Capital_Ma for Oncternal Therapeutics Inc. is performing very badly with a performance of -62.03%. Brookline_Capital_Ma has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Oncternal Therapeutics Inc. | - | - | - |
| iShares Core DAX® | 0.060% | 1.215% | 18.128% |
| iShares Nasdaq 100 | -3.065% | -0.519% | 2.080% |
| iShares Nikkei 225® | -2.094% | -3.066% | 11.655% |
| iShares S&P 500 | -1.657% | -0.069% | 1.103% |
Comments by Brookline_Capital_Ma for this prediction
In the thread Oncternal Therapeutics Inc. diskutieren
Oncternal Therapeutics, Inc. (NASDAQ: ONCT) had its "buy" rating re-affirmed by analysts at Brookline Capital Management.
Ratings data for ONCT provided by MarketBeat
In the thread Trading Oncternal Therapeutics Inc.
Die von Brookline_Capital_Ma gewählte maximale Laufzeit wurde überschritten
Stopped prediction by Brookline_Capital_Ma for Oncternal Therapeutics Inc.
Oncternal Therapeutics Inc.
Start price
Target price
Perf. (%)
€0.31
04.12.23
04.12.23
€1.85
04.12.24
04.12.24
3.23%
05.12.24
05.12.24

